VBI Vaccines (NASDAQ:VBIV) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a report issued on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

VBI Vaccines Price Performance

The firm has a 50 day simple moving average of $0.24 and a 200-day simple moving average of $0.49. VBI Vaccines has a 12-month low of $0.06 and a 12-month high of $1.35.

About VBI Vaccines

VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.